ILC 2023 - Archived - International Invasive Lobular Breast Cancer (ILC) Symposium 2024

Celebrating the Success of the ILC Symposium 2023!

Thank you for your enthusiastic participation in the ILC Symposium 2023. Your presence, diverse perspectives, and unwavering support played a pivotal role in making the symposium a resounding success. Our thanks to all researchers, patient advocates, and clinicians for their active involvement.

We were honored to have hosted 221 attendees in person and 51 virtually, creating a vibrant global exchange of knowledge. The symposium was enriched by the participation of individuals from 15 different countries, fostering a truly international dialogue.

Together, we’re advancing understanding of ILC, improving treatments, and enhancing support for those affected. We look forward to the positive outcomes and collaborations arising from this symposium.

With warm regards,

Organizing Committee ILC 2023

Watch the recorded sessions below

Thank you to the presenters who agreed to record and share their presentations. Not all presentations were recorded. Please contact the presenters directly with questions. For the complete agenda, click here.

Keynote Speakers

Cathrin Brisken, M.D., Ph. D. — **Cathrin Brisken, MD, PhD**
Swiss Federal Institute of Technology Lausanne (EFPL), Switzerland, Inst. of Cancer Research, London, UK

**Cathrin Brisken, MD, PhD**
Swiss Federal Institute of Technology Lausanne (EFPL), Switzerland, Inst. of Cancer Research, London, UK

Speakers, Chairs, & Moderators

**Rohit Bhargava, MD**
UPMC, Magee-Womens Hospital, Pittsburgh, PA, USA

Val Brunton, Ph.D. — **Rohit Bhargava, MD**
UPMC, Magee-Womens Hospital, Pittsburgh, PA, USA

Agenda – Click here for PDF

Abstract Booklet – Click here for PDF

ILC 2023 Posters

The poster PDFs provided here have been shared with the consent of the authors. This collection includes poster PDFs for 29 out of 50 posters, depending on which authors granted permission for their poster PDFs to be published.

Poster Number	PrimaryAuthor	Title	Category
1	Gitte Zels	Overview of patients with invasive lobular breast carcinoma included in the post-mortem tissue donation program, UPTIDER	Clinical Characteristics
2	Qian Zhao	Clinical Characteristics and Outcomes of Invasive Lobular Carcinoma	Clinical Characteristics
3	Jasmine Timbres	Risk factors pre-disposing to LCIS and ILC	Clinical Characteristics
4	Josephine Van Cauwenberge	Reporting on invasive lobular carcinoma in clinical drug trials and trials investigating gene expression profiles and molecular screening programs – a systematic review	Clinical Characteristics
5	Siobhan Freeney	Enhancing Knowledge and Research in Europe for Invasive Lobular Breast Cancer: Unique Challenges across European Countries	Clinical Characteristics
6	Helen Coulthard	“they… kept saying there’s nothing there”: British Women’s accounts of delayed lobular breast cancer diagnosis	Diagnosis
7	Laurie Hutcheson	Individuals with Invasive Lobular Carcinoma (ILC) Raise their Voices about ILC and Surgery	Diagnosis
8	Luca Nicosia	Contrast-Enhanced Mammography (CEM) compared to Breast Magnetic Resonance (MRI) in the management of breast lobular neoplasia: a new scenario in facing the diagnosis of an insidious disease	Diagnosis
10	Annapurna Gupta	Downregulation of Arginosuccinate synthase 1 confers Tamoxifen Resistance in Invasive Lobular Breast Cancer	Treatment Strategies
11	Bernadette Heemskerk-Gerritsen	The effect of (neo)adjuvant chemotherapy on long-term survival outcomes in Invasive Lobular Breast Cancer Patients treated with endocrine therapy: a retrospective cohort study	Treatment Strategies
13	Christina Gersch	Characterization of Resistance to CDK4/6 Inhibitors and Endocrine Therapy in Invasive Lobular Breast Cancers Cell Lines	Treatment Strategies
16	Melinda Sanders	High prevalence of HER2-low among ILC with residual disease following neoadjuvant therapy provides therapeutic opportunities with HER2-antibody-drug conjugates	Treatment Strategies
17	William Yang	E-cadherin loss imparts mitotic vulnerabilities rendering breast cancer cells synthetic lethal to crizotinib and up-regulation of Src signalling reverses this effect	Treatment Strategies
20	Francesca Magnoni	Comparison of long-term outcome between high risk lobular versus ductal breast cancer: a propensity score matched study	Prognosis
21	Rebecca Riggins	Glutamate metabolic enzymes associate with increased tumor size in black women with invasive lobular breast cancer: a single-institution study	Prognosis
22	Simran Sandhu	Racial Disparities in Survival in Lobular Breast Cancer	Prognosis
23	Baylee Porter	Glucocorticoid receptor activation inhibits tumor cell growth while increasing metastatic characteristics in models of invasive lobular breast cancer	Metastasis
24	Bernadette Heemskerk-Gerritsen	Localization of metastatic disease in patients with a history of lobular carcinoma of the breast	Metastasis
27	Andi Cani	Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance	Biomarker
28	Chinasa A Ufondu	Assessing the Effect of E-cadherin loss on Estrogen Receptor activity in Human Mammary Epithelial Cell Models	Biomarker
30	Luyu Jia	Mutating E-cadherin in Rats to Model Lobular Breast Cancer	Biomarker
31	Madeleine Shackleford	WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in invasive lobular carcinoma cells	Biomarker
32	Maggie Musick	E-cadherin suppression supports transcriptional programs of lineage plasticity in early ILC tumorigenesis	Biomarker
36	Matteo Serra	Spatially resolved analysis of tumor microenvironment revealed biologically driven subgroups with distinct clinical outcome in invasive lobular carcinoma	TME
37	Emmanuelle mouret-fourme	Clinical Characteristics of Lobular Breast Carcinoma in CDH1 genetic predisposition. Experience from the Institut Curie	Genetics
40	Rita Canas-Marques	Aberrant E-cadherin (E-cad) Expression in Lobular Carcinoma in Situ (LCIS): A Comprehensive Evaluation of N-terminal, Extracellular, and C-terminal E-cadherin Domains	Genetics
41	Jing Yu	Lobular-like invasive mammary carcinoma: Is this a ductal cancer, lobular cancer, or a distinct entity?	Genetics
44	Sanghoon Lee	Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas	Epigenomics
48	Sarah Nash	Transcriptomic and immune heterogeneity underpin the biology of pleomorphic invasive lobular breast cancer	Multiomics

Travel Fellowship Awardees

We are thrilled to announce the distinguished recipients of the Travel Fellowship for the upcoming ILC Symposium 2023. These exceptional individuals have demonstrated outstanding dedication and contributions to the field of invasive lobular breast cancer research.

Awardees attending from within the USA will receive $800, while international attendees will receive $1200 in fellowship amounts. These fellowships aim to assist participants in covering their expenses and fostering a diverse and inclusive environment for knowledge exchange.

Join us in congratulating the following scholars who have been selected to receive the prestigious Travel Fellowship Award, listed below and here.

Their commitment and passion exemplify the spirit of collaboration and knowledge-sharing that the ILC Symposium stands for. We eagerly anticipate their participation and look forward to their valuable contributions at the symposium.
We extend our heartfelt appreciation to all applicants for their exceptional submissions and encourage everyone to be part of this inspiring event.

For Breast Cancer Advocates

CLICK HERE for the ILC Workshop Agenda.

Presentations from the Symposium

Session 1 Slides

Digital Toolkit for Advocates

We are delighted to present the “Digital Toolkit for Advocates” designed exclusively for patient advocates attending the ILC Symposium 2023. This comprehensive toolkit is aimed at enhancing your symposium experience by providing valuable resources and empowering you in your advocacy journey.

Inside the toolkit, you’ll find a treasure trove of resources, including:

📽️ Video Recordings: Access video recordings of past symposium sessions to catch up on valuable insights shared by renowned experts in the field.

🎧 Instructive Recordings: Dive deeper into instructive sessions that offer valuable tips and advice on patient advocacy, communication, and empowerment.

🔗 Links to Advocacy Resources: Discover a curated collection of links to advocacy resources, including Facebook groups and other online platforms where you can connect with like-minded advocates.

💡 Useful Resources: Find a compilation of valuable resources, documents, and informative materials that can aid you in your advocacy efforts.

This Digital Toolkit is your companion throughout the symposium and beyond, offering a wealth of knowledge and support to enhance your advocacy journey. We hope these resources empower you to make a positive impact in the field of invasive lobular breast cancer research.

Click here to access the Digital Toolkit for Advocates

International Organizing Committee

**Steffi Oesterreich, PhD**
***Chair***
Professor, Univ of Pittsburgh, Co-Director, Womens Cancer Resarch Center, Co-Leader Cancer Biology Program, UPMC HCC and MWRI

**Steffi Oesterreich, PhD**
***Chair***
Professor, Univ of Pittsburgh, Co-Director, Womens Cancer Resarch Center, Co-Leader Cancer Biology Program, UPMC HCC and MWRI

Local Organizing Committee

**Daniel D. Brown, PhD**
**Website and Media Manager**
Senior Research Scientist, Institute for Precision Medicine, University of Pittsburgh/UPMC Hillman Cancer Center
**Laughing Mantis Studio**

GlobMob (Patient Advocate) Organizing Committee

**Lori Petitti**
***Co-chair***
Independent ILC advocate (also: Breast Cancer Care & Research Fund BCCRF)

Advisors

The Assembly

5051 Centre Avenue
Pittsburgh, PA 15213

A historical venue to create memories: The ILC symposium 2023 will be held at The Assembly building in Pittsburgh. This is a unique venue with a rich history unlike any other. A century ago, The Assembly was Ford automotive’s first Model T assembly plant in the US. Over the years the building has become a clothing store and a stationary store. Today, the building has been transformed into a cutting-edge research facility, housing researchers working on cancer and other diseases. We hope this venue will facilitate innovative ideas, new collaboration and relationships, and many priceless memories. Read more on the fascinating history of the venue here: The Assembly: A former Model T factory builds the next generation of cancer treatments.